<DOC>
	<DOC>NCT00195845</DOC>
	<brief_summary>The purpose of this study is to determine if galantamine augmentaion improves cognition in euthymic bipolar patients. In addition, the effect of galantamine on clinical measures of functioning and psychopathology will also be assessed.</brief_summary>
	<brief_title>A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder</brief_title>
	<detailed_description>The study length is 12 to 24 weeks depending on whether patients enter the crossover. Study also involves 3 neuropsychology testings. Reimbursement is $20 a visit and $50 each testing.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Age 1860; DSMIV diagnosis of bipolar disorder, any subtype; Baseline Mini Mental Status exam above 20; MRS &lt; 16; MADRS &lt; 16 Current substance dependence; serious unstable medical conditions; active suicidal ideation; current DSMIV for a major mood episodes; history of COPD, epilepsy, cardiac arrhythmia, and peptic ulcer disease; meet DSMIV criteria for dementia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>